NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to ...
AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...
More than five million people worldwide have RA, and most of them are considered to be in the prime of their working lives (between 30-50 years of age). The data are from DE032, an economic companion ...
AbbVie’s blockbuster arthritis medication, adalimumab (Humira), now has an FDA-approved competitor: Amgen’s adalimumab-atto, also called Amjevita. AbbVie’s blockbuster arthritis medication, adalimumab ...
To ensure Humira maintains its potency and effectiveness when you’re ready to inject it, you will need to keep it ...
NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In 2021, Humira — the blockbuster biologic that has for ...
HUMIRA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. HUMIRA has been shown to reduce the rate of progression of joint damage as ...
The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...
Yuflyma is Celltrion USA's high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar JERSEY CITY, N.J.--(BUSINESS WIRE)--Celltrion USA today announced the launch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback